Johnson & Johnson is taking a deep dive into antivirals, trading $1.75 billion for private biotech Alios BioPharma to get its hands on a midstage treatment and some early assets that could expand its share of the blockbuster hepatitis C market.

…read more

Source: J&J makes a splash in hep C with a $1.75B deal for Alios


0 No comments